The Short-term Effects of Vitamin D Repletion on Cholesterol: a Randomized, Placebo-controlled Trial
Overview
Affiliations
Objective: Vitamin D deficiency is common and associated with dyslipidemia. However, it is unclear whether oral vitamin D supplementation improves the lipid profile. Therefore, we conducted a randomized, placebo-controlled trial to determine the short-term effects of vitamin D repletion on the lipid profile.
Methods And Results: One hundred fifty-one vitamin D-deficient (25-hydroxyvitamin D <20 ng/mL) adults with elevated risk for cardiovascular disease were randomized to receive either 50 000 IU of vitamin D3 weekly for 8 weeks or placebo. The primary outcome was the change in small low-density lipoprotein (LDL) particle number. Secondary outcomes included changes in other nuclear magnetic resonance-based and chemical lipid fractions. Vitamin D failed to improve the lipid profile. Compared with the placebo, vitamin D repletion did not change small LDL particle number (mean change, +18 nmol/L; 95% CI [-80 to +116 nmol/L]; P=0.63). There were also no changes in the chemical lipid profile: total cholesterol (+5.8 mg/dL, 95% CI [-1.4 to +13.0 mg/dL], P=0.14); LDL cholesterol (+3.8 mg/dL, 95% CI [-2.5 to +10.2 mg/dL], P=0.13); high-density lipoprotein cholesterol (+0.4 mg/dL 95% CI [-1.6 to +2.6 mg/dL], P=0.71); and triglycerides (+7.9 mg/dL 95% CI [-6.5 to +22.3 mg/dL]). In the vitamin D repletion group, exploratory multivariate regression analysis demonstrates that changes in LDL cholesterol were positively correlated with the changes in serum calcium (P<0.001) and inversely with the changes in serum parathyroid hormone (P=0.02).
Conclusions: In contrast to the association between low 25-hydroxyvitamin D levels and dyslipidemia, correcting vitamin D deficiency in the short-term does not improve the lipid profile. Repletion of 25-hydroxyvitamin D levels raised serum calcium levels and decreased serum parathyroid hormone levels. These expected physiological responses to vitamin D therapy were correlated with a significant increase in LDL cholesterol. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT01008384.
A cohort study of serum 25-hydroxyvitamin D levels and the risk of hyperlipidaemia in adults.
Liu Z, Liu S, Yao X, Wang C, Song Y, Bi Y Front Nutr. 2025; 11:1492621.
PMID: 39925969 PMC: 11802281. DOI: 10.3389/fnut.2024.1492621.
VITAMIN D DEFICIENCY AS AN INDEPENDENT PREDICTOR OF CARDIOVASCULAR DISEASE.
Frentusca C, Babes K, Galusca D Acta Endocrinol (Buchar). 2024; 19(3):319-325.
PMID: 38356981 PMC: 10863965. DOI: 10.4183/aeb.2023.319.
Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst K, Knutsen H EFSA J. 2023; 21(8):e08145.
PMID: 37560437 PMC: 10407748. DOI: 10.2903/j.efsa.2023.8145.
New Insights into Pathophysiology and New Risk Factors for ACS.
Nardin M, Verdoia M, Laera N, Cao D, De Luca G J Clin Med. 2023; 12(8).
PMID: 37109221 PMC: 10146393. DOI: 10.3390/jcm12082883.
Vitamin D, Cholesterol, and DXA Value Relationship with Bimaxillary Cone Beam CT Values.
Sghaireen M, Ganji K, Srivastava K, Alam M, Nashwan S, Migdadi F J Clin Med. 2023; 12(7).
PMID: 37048761 PMC: 10094997. DOI: 10.3390/jcm12072678.